Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Primary Biliary Cholangitis Therapeutic Market

ID: MRFR/HC/41680-HCR
200 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Primary Biliary Cholangitis Therapeutic Market Research Report: Size, Share, Trend Analysis By Therapeutic Class (Ursodeoxycholic Acid, Obeticholic Acid, Antihistamines, Immunosuppressants), By Route of Administration (Oral, Intravenous, Subcutaneous), By Indication (Cholestatic Liver Disease, Liver Cirrhosis, Fatigue Related Therapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Primary Biliary Cholangitis Therapeutic Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Therapeutic Class (USD Billion)
  49.     4.1.1 Ursodeoxycholic Acid
  50.     4.1.2 Obeticholic Acid
  51.     4.1.3 Antihistamines
  52.     4.1.4 Immunosuppressants
  53.   4.2 Healthcare, BY Route of Administration (USD Billion)
  54.     4.2.1 Oral
  55.     4.2.2 Intravenous
  56.     4.2.3 Subcutaneous
  57.   4.3 Healthcare, BY Indication (USD Billion)
  58.     4.3.1 Cholestatic Liver Disease
  59.     4.3.2 Liver Cirrhosis
  60.     4.3.3 Fatigue Related Therapy
  61.   4.4 Healthcare, BY Distribution Channel (USD Billion)
  62.     4.4.1 Hospital Pharmacy
  63.     4.4.2 Retail Pharmacy
  64.     4.4.3 Online Pharmacy
  65.   4.5 Healthcare, BY Region (USD Billion)
  66.     4.5.1 North America
  67.       4.5.1.1 US
  68.       4.5.1.2 Canada
  69.     4.5.2 Europe
  70.       4.5.2.1 Germany
  71.       4.5.2.2 UK
  72.       4.5.2.3 France
  73.       4.5.2.4 Russia
  74.       4.5.2.5 Italy
  75.       4.5.2.6 Spain
  76.       4.5.2.7 Rest of Europe
  77.     4.5.3 APAC
  78.       4.5.3.1 China
  79.       4.5.3.2 India
  80.       4.5.3.3 Japan
  81.       4.5.3.4 South Korea
  82.       4.5.3.5 Malaysia
  83.       4.5.3.6 Thailand
  84.       4.5.3.7 Indonesia
  85.       4.5.3.8 Rest of APAC
  86.     4.5.4 South America
  87.       4.5.4.1 Brazil
  88.       4.5.4.2 Mexico
  89.       4.5.4.3 Argentina
  90.       4.5.4.4 Rest of South America
  91.     4.5.5 MEA
  92.       4.5.5.1 GCC Countries
  93.       4.5.5.2 South Africa
  94.       4.5.5.3 Rest of MEA
  95. 5 SECTION V: COMPETITIVE ANALYSIS
  96.   5.1 Competitive Landscape
  97.     5.1.1 Overview
  98.     5.1.2 Competitive Analysis
  99.     5.1.3 Market share Analysis
  100.     5.1.4 Major Growth Strategy in the Healthcare
  101.     5.1.5 Competitive Benchmarking
  102.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  103.     5.1.7 Key developments and growth strategies
  104.       5.1.7.1 New Product Launch/Service Deployment
  105.       5.1.7.2 Merger & Acquisitions
  106.       5.1.7.3 Joint Ventures
  107.     5.1.8 Major Players Financial Matrix
  108.       5.1.8.1 Sales and Operating Income
  109.       5.1.8.2 Major Players R&D Expenditure. 2023
  110.   5.2 Company Profiles
  111.     5.2.1 Intercept Pharmaceuticals (US)
  112.       5.2.1.1 Financial Overview
  113.       5.2.1.2 Products Offered
  114.       5.2.1.3 Key Developments
  115.       5.2.1.4 SWOT Analysis
  116.       5.2.1.5 Key Strategies
  117.     5.2.2 Zymeworks (CA)
  118.       5.2.2.1 Financial Overview
  119.       5.2.2.2 Products Offered
  120.       5.2.2.3 Key Developments
  121.       5.2.2.4 SWOT Analysis
  122.       5.2.2.5 Key Strategies
  123.     5.2.3 Gilead Sciences (US)
  124.       5.2.3.1 Financial Overview
  125.       5.2.3.2 Products Offered
  126.       5.2.3.3 Key Developments
  127.       5.2.3.4 SWOT Analysis
  128.       5.2.3.5 Key Strategies
  129.     5.2.4 Bristol-Myers Squibb (US)
  130.       5.2.4.1 Financial Overview
  131.       5.2.4.2 Products Offered
  132.       5.2.4.3 Key Developments
  133.       5.2.4.4 SWOT Analysis
  134.       5.2.4.5 Key Strategies
  135.     5.2.5 Novartis (CH)
  136.       5.2.5.1 Financial Overview
  137.       5.2.5.2 Products Offered
  138.       5.2.5.3 Key Developments
  139.       5.2.5.4 SWOT Analysis
  140.       5.2.5.5 Key Strategies
  141.     5.2.6 AbbVie (US)
  142.       5.2.6.1 Financial Overview
  143.       5.2.6.2 Products Offered
  144.       5.2.6.3 Key Developments
  145.       5.2.6.4 SWOT Analysis
  146.       5.2.6.5 Key Strategies
  147.     5.2.7 Horizon Therapeutics (IE)
  148.       5.2.7.1 Financial Overview
  149.       5.2.7.2 Products Offered
  150.       5.2.7.3 Key Developments
  151.       5.2.7.4 SWOT Analysis
  152.       5.2.7.5 Key Strategies
  153.     5.2.8 Madrigal Pharmaceuticals (US)
  154.       5.2.8.1 Financial Overview
  155.       5.2.8.2 Products Offered
  156.       5.2.8.3 Key Developments
  157.       5.2.8.4 SWOT Analysis
  158.       5.2.8.5 Key Strategies
  159.   5.3 Appendix
  160.     5.3.1 References
  161.     5.3.2 Related Reports
  162. 6 LIST OF FIGURES
  163.   6.1 MARKET SYNOPSIS
  164.   6.2 NORTH AMERICA MARKET ANALYSIS
  165.   6.3 US MARKET ANALYSIS BY THERAPEUTIC CLASS
  166.   6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  167.   6.5 US MARKET ANALYSIS BY INDICATION
  168.   6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  169.   6.7 CANADA MARKET ANALYSIS BY THERAPEUTIC CLASS
  170.   6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  171.   6.9 CANADA MARKET ANALYSIS BY INDICATION
  172.   6.10 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  173.   6.11 EUROPE MARKET ANALYSIS
  174.   6.12 GERMANY MARKET ANALYSIS BY THERAPEUTIC CLASS
  175.   6.13 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  176.   6.14 GERMANY MARKET ANALYSIS BY INDICATION
  177.   6.15 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  178.   6.16 UK MARKET ANALYSIS BY THERAPEUTIC CLASS
  179.   6.17 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  180.   6.18 UK MARKET ANALYSIS BY INDICATION
  181.   6.19 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  182.   6.20 FRANCE MARKET ANALYSIS BY THERAPEUTIC CLASS
  183.   6.21 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  184.   6.22 FRANCE MARKET ANALYSIS BY INDICATION
  185.   6.23 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  186.   6.24 RUSSIA MARKET ANALYSIS BY THERAPEUTIC CLASS
  187.   6.25 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  188.   6.26 RUSSIA MARKET ANALYSIS BY INDICATION
  189.   6.27 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  190.   6.28 ITALY MARKET ANALYSIS BY THERAPEUTIC CLASS
  191.   6.29 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  192.   6.30 ITALY MARKET ANALYSIS BY INDICATION
  193.   6.31 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  194.   6.32 SPAIN MARKET ANALYSIS BY THERAPEUTIC CLASS
  195.   6.33 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  196.   6.34 SPAIN MARKET ANALYSIS BY INDICATION
  197.   6.35 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  198.   6.36 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC CLASS
  199.   6.37 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  200.   6.38 REST OF EUROPE MARKET ANALYSIS BY INDICATION
  201.   6.39 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  202.   6.40 APAC MARKET ANALYSIS
  203.   6.41 CHINA MARKET ANALYSIS BY THERAPEUTIC CLASS
  204.   6.42 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  205.   6.43 CHINA MARKET ANALYSIS BY INDICATION
  206.   6.44 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  207.   6.45 INDIA MARKET ANALYSIS BY THERAPEUTIC CLASS
  208.   6.46 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  209.   6.47 INDIA MARKET ANALYSIS BY INDICATION
  210.   6.48 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  211.   6.49 JAPAN MARKET ANALYSIS BY THERAPEUTIC CLASS
  212.   6.50 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  213.   6.51 JAPAN MARKET ANALYSIS BY INDICATION
  214.   6.52 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  215.   6.53 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC CLASS
  216.   6.54 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  217.   6.55 SOUTH KOREA MARKET ANALYSIS BY INDICATION
  218.   6.56 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  219.   6.57 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC CLASS
  220.   6.58 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  221.   6.59 MALAYSIA MARKET ANALYSIS BY INDICATION
  222.   6.60 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  223.   6.61 THAILAND MARKET ANALYSIS BY THERAPEUTIC CLASS
  224.   6.62 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  225.   6.63 THAILAND MARKET ANALYSIS BY INDICATION
  226.   6.64 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  227.   6.65 INDONESIA MARKET ANALYSIS BY THERAPEUTIC CLASS
  228.   6.66 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  229.   6.67 INDONESIA MARKET ANALYSIS BY INDICATION
  230.   6.68 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  231.   6.69 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC CLASS
  232.   6.70 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  233.   6.71 REST OF APAC MARKET ANALYSIS BY INDICATION
  234.   6.72 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  235.   6.73 SOUTH AMERICA MARKET ANALYSIS
  236.   6.74 BRAZIL MARKET ANALYSIS BY THERAPEUTIC CLASS
  237.   6.75 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  238.   6.76 BRAZIL MARKET ANALYSIS BY INDICATION
  239.   6.77 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  240.   6.78 MEXICO MARKET ANALYSIS BY THERAPEUTIC CLASS
  241.   6.79 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  242.   6.80 MEXICO MARKET ANALYSIS BY INDICATION
  243.   6.81 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  244.   6.82 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC CLASS
  245.   6.83 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  246.   6.84 ARGENTINA MARKET ANALYSIS BY INDICATION
  247.   6.85 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  248.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC CLASS
  249.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  250.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
  251.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  252.   6.90 MEA MARKET ANALYSIS
  253.   6.91 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC CLASS
  254.   6.92 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  255.   6.93 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
  256.   6.94 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  257.   6.95 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC CLASS
  258.   6.96 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  259.   6.97 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
  260.   6.98 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  261.   6.99 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC CLASS
  262.   6.100 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  263.   6.101 REST OF MEA MARKET ANALYSIS BY INDICATION
  264.   6.102 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  265.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  266.   6.104 RESEARCH PROCESS OF MRFR
  267.   6.105 DRO ANALYSIS OF HEALTHCARE
  268.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  269.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  270.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  271.   6.109 HEALTHCARE, BY THERAPEUTIC CLASS, 2024 (% SHARE)
  272.   6.110 HEALTHCARE, BY THERAPEUTIC CLASS, 2024 TO 2035 (USD Billion)
  273.   6.111 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  274.   6.112 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  275.   6.113 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
  276.   6.114 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
  277.   6.115 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  278.   6.116 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
  279.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  280. 7 LIST OF TABLES
  281.   7.1 LIST OF ASSUMPTIONS
  282.     7.1.1
  283.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  284.     7.2.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  285.     7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  286.     7.2.3 BY INDICATION, 2025-2035 (USD Billion)
  287.     7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  288.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  289.     7.3.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  290.     7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  291.     7.3.3 BY INDICATION, 2025-2035 (USD Billion)
  292.     7.3.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  293.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  294.     7.4.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  295.     7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  296.     7.4.3 BY INDICATION, 2025-2035 (USD Billion)
  297.     7.4.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  298.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  299.     7.5.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  300.     7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  301.     7.5.3 BY INDICATION, 2025-2035 (USD Billion)
  302.     7.5.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  303.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  304.     7.6.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  305.     7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  306.     7.6.3 BY INDICATION, 2025-2035 (USD Billion)
  307.     7.6.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  308.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  309.     7.7.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  310.     7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  311.     7.7.3 BY INDICATION, 2025-2035 (USD Billion)
  312.     7.7.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  313.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  314.     7.8.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  315.     7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  316.     7.8.3 BY INDICATION, 2025-2035 (USD Billion)
  317.     7.8.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  318.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  319.     7.9.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  320.     7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  321.     7.9.3 BY INDICATION, 2025-2035 (USD Billion)
  322.     7.9.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  323.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  324.     7.10.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  325.     7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  326.     7.10.3 BY INDICATION, 2025-2035 (USD Billion)
  327.     7.10.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  328.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  329.     7.11.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  330.     7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  331.     7.11.3 BY INDICATION, 2025-2035 (USD Billion)
  332.     7.11.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  333.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  334.     7.12.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  335.     7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  336.     7.12.3 BY INDICATION, 2025-2035 (USD Billion)
  337.     7.12.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  338.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  339.     7.13.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  340.     7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  341.     7.13.3 BY INDICATION, 2025-2035 (USD Billion)
  342.     7.13.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  343.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  344.     7.14.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  345.     7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  346.     7.14.3 BY INDICATION, 2025-2035 (USD Billion)
  347.     7.14.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  348.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  349.     7.15.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  350.     7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  351.     7.15.3 BY INDICATION, 2025-2035 (USD Billion)
  352.     7.15.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  353.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  354.     7.16.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  355.     7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  356.     7.16.3 BY INDICATION, 2025-2035 (USD Billion)
  357.     7.16.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  358.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  359.     7.17.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  360.     7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  361.     7.17.3 BY INDICATION, 2025-2035 (USD Billion)
  362.     7.17.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  363.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  364.     7.18.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  365.     7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  366.     7.18.3 BY INDICATION, 2025-2035 (USD Billion)
  367.     7.18.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  368.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  369.     7.19.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  370.     7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  371.     7.19.3 BY INDICATION, 2025-2035 (USD Billion)
  372.     7.19.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  373.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  374.     7.20.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  375.     7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  376.     7.20.3 BY INDICATION, 2025-2035 (USD Billion)
  377.     7.20.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  378.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  379.     7.21.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  380.     7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  381.     7.21.3 BY INDICATION, 2025-2035 (USD Billion)
  382.     7.21.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  383.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  384.     7.22.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  385.     7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  386.     7.22.3 BY INDICATION, 2025-2035 (USD Billion)
  387.     7.22.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  388.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  389.     7.23.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  390.     7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  391.     7.23.3 BY INDICATION, 2025-2035 (USD Billion)
  392.     7.23.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  393.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  394.     7.24.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  395.     7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  396.     7.24.3 BY INDICATION, 2025-2035 (USD Billion)
  397.     7.24.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  398.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  399.     7.25.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  400.     7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  401.     7.25.3 BY INDICATION, 2025-2035 (USD Billion)
  402.     7.25.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  403.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  404.     7.26.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  405.     7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  406.     7.26.3 BY INDICATION, 2025-2035 (USD Billion)
  407.     7.26.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  408.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  409.     7.27.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  410.     7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  411.     7.27.3 BY INDICATION, 2025-2035 (USD Billion)
  412.     7.27.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  413.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  414.     7.28.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  415.     7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  416.     7.28.3 BY INDICATION, 2025-2035 (USD Billion)
  417.     7.28.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  418.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  419.     7.29.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  420.     7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  421.     7.29.3 BY INDICATION, 2025-2035 (USD Billion)
  422.     7.29.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  423.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  424.     7.30.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  425.     7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  426.     7.30.3 BY INDICATION, 2025-2035 (USD Billion)
  427.     7.30.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  428.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  429.     7.31.1
  430.   7.32 ACQUISITION/PARTNERSHIP
  431.     7.32.1

Healthcare Market Segmentation

Healthcare By Therapeutic Class (USD Billion, 2025-2035)

  • Ursodeoxycholic Acid
  • Obeticholic Acid
  • Antihistamines
  • Immunosuppressants

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Intravenous
  • Subcutaneous

Healthcare By Indication (USD Billion, 2025-2035)

  • Cholestatic Liver Disease
  • Liver Cirrhosis
  • Fatigue Related Therapy

Healthcare By Distribution Channel (USD Billion, 2025-2035)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions